TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

TAVR controversy: Surgeon fired after saying cardiologist treated patients without proper credentials

An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet. 

Thumbnail

TAVR among 90-year-old patients: An updated look at mortality, hospital costs and more

In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 

The DurAVR transcatheter heart valve (THV), developed by Minnesota-based Anteris Technologies

New biomimetic TAVR valve, the first of its kind, linked to strong performance after 1 year

The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.

Abbott TriClip device for TEER

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TVT 2023: Cardiovascular Research Foundation announces late-breaking clinical trials

In addition to these 15 late-breaking clinical studies, TVT 2023 will feature live cases, hands-on training, poster presentations and much more.

Data on a next-generation balloon-expandable transcatheter heart valve

Next-gen TAVR valve, tested on patients for very first time, linked to high success rate

A new-look TAVR valve was tested on patients for the first time, leading researchers to say its use appears to be "feasible and safe." More research, of course, is still required. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Is TAVR too common among younger, low-risk patients? 2 experts share their concerns

Two experienced TAVR specialists—Sachin Goel, MD, and Michael Reardon, MD—examined the growing trend of younger, low-risk patients being recommended for TAVR over SAVR.

X-ray photon trajectory during the simulation phantom study from the side and top views. Due to scattering of the X-rays when they hit the lower end of the patient bed, exposure in mainly to the lower body of the interventional echocardiographer performing transesophageal echocardiography. The green lines are the scattered photon trajectories calculated by Monte Carlo simulation in the study.

Radiation exposure in the cath lab: Tracking the impact on interventional echocardiographers

Researchers found that echocardiographers in the cath lab are exposed to high doses of radiation on the right half of their body, especially the waist and lower body.